Clarus Therapeutics Holdings Inc

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-  Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years -  JATENZO is  an oral softgel testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) -  Compelling fit with Tolmar's strategy to acquire and develop therapies targeting diseases and conditions in Urology, Oncology and Orphan Diseases leveraging the company's focus and commitment in Urology community and Men's Health BUFFALO GROVE, Ill. , Oct. 28, 2022 /PRNewswire/ -- Tolmar Pharmaceuticals, Inc., a fully integrated pharmaceutical company, through its affiliate, Tolmar, Inc., today announced the acquisition of all rights to JATENZO® from Clarus Therapeutics Holdings, Inc. (OTC: CRXTQ) and its wholly-owned subsidiary Clarus Therapeutics, Inc. (collectively, "Clarus").

Tolmar Announces Acquisition of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio

News for Clarus Therapeutics Holdings Inc Stock (CRXTQ)